Skip to main content
. 2020 May 13;29(10):2651–2660. doi: 10.1007/s11136-020-02520-7

Fig. 1.

Fig. 1

Adjusted LS Mean Change from Baseline in QLQ-C30 GHS. Repeated measures mixed model with treatment by objective treatment response interaction, treatment by week interaction controlling for baseline QLQ-C30 GHS, comorbidity index, ECOG at baseline, age, AJCC stage, autoimmune comorbidity, therapy objective response to therapy. Positive number represents improvement in score, negative number represents deterioration. GHS/QoL global health quality of life scale, LS least squares, PEMBRO pembrolizumab, IPI + NIVO ipilimumab and nivolumab, CI confidence interval